Research programme: autoimmune disorder therapeutics - Lycera/Merck & CoAlternative Names: RORγt inhibitors - Lycera/Merck & Co
Latest Information Update: 15 Feb 2013
At a glance
- Originator Lycera
- Developer Lycera; Merck & Co
- Class Small molecules
- Mechanism of Action Retinoic acid receptor gamma antagonists; Th17 cell inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders